原发免疫性血小板减少症医患调研:I-WISh国际调研中国亚组分析
该研究为I-WISh国际调研的中国亚组分析,纳入102名医生和286例ITP患者,采用描述性分析探讨ITP对生活质量和情绪的影响及医患治疗认知差异。结果显示疲劳和焦虑是主要症状但医生报告不足,超90%患者认为ITP对生活多方面有负面影响,医患在治疗选择上存在差异。
要点
- 疲劳和对血小板计数不稳定的焦虑是ITP患者治疗后主要症状,医生报告不充足。
- 超90%患者认为ITP对工作学习、日常事务、体能、运动和性生活有负面影响。
- 医生认为糖皮质激素最可能实现持续缓解,患者对TPO-RA反馈最好且83.9%满意。
核心结论
- 中国医生对ITP患者疲劳和焦虑症状认识不足,ITP对患者生活质量和情绪有显著负面影响。
- 医患在治疗选择上存在差异,提示应加强沟通、共同决策以制定个体化治疗方案。
研究设计与样本
- I-WISh国际调研的中国亚组分析,采用描述性分析。
- 共纳入102名医生和286例ITP患者参与调研。
主要发现
- 疲劳和对血小板计数不稳定的焦虑是治疗后主要症状,医生报告不充足。
- 超过90.0%的患者认为ITP对工作或学习、日常事务、体能、运动能力和性生活产生负面影响。
- 60.8%(174/286)患者认为ITP对情绪影响较大,担忧血小板计数波动(74.8%,214/286)、疾病本身(71.7%,205/286)及病情恶化(68.9%,197/268)。
- 医患均认为减少自发出血、维持安全稳定的血小板水平和改善生活质量是前三位治疗目标。
- 医生认为糖皮质激素(54.9%,56/102)最可能达到持续有效治疗,83.9%(240/286)患者对TPO-RA疗效满意。
关键数值与推荐
- 超过90.0%患者报告ITP对工作学习、日常事务、体能、运动能力和性生活有负面影响。
- 60.8%(174/286)患者认为ITP对情绪影响较大。
- 74.8%(214/286)患者担忧血小板计数波动,71.7%(205/286)担忧疾病本身,68.9%(197/268)担忧病情恶化。
- 54.9%(56/102)医生认为糖皮质激素最可能实现持续有效治疗。
- 83.9%(240/286)患者对TPO-RA总体疗效满意。
临床怎么用
- 临床应关注ITP患者疲劳和焦虑症状,提高对其生活质量和情绪影响的识别。
- 治疗决策中应纳入减少自发出血、维持安全稳定血小板水平和改善生活质量三大目标。
- 医患应加强沟通,通过共同决策制定个体化治疗方案。
局限性
- 本研究为描述性分析,未报告统计推断或混杂因素控制。
- 原文未报告样本代表性、应答率或数据收集方式等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the impact of primary immune thrombocytopenia (ITP) on patient's quality of life and emotional well-being, and both the physician and the patient's perception of the treatment. Methods: This study was a Chinese Subgroup analysis of I-WISh survey, including 102 physicians and 286 ITP patients invited to complete the survey. A descriptive analysis of the results of the physician-patient survey was conducted in three parts: symptoms, impact of ITP on quality of life and emotion, and treatment perception. Results: Fatigue and anxiety about unstable platelet counts were the main symptoms after treatment. Physicians reported inadequate frequency of anxiety and fatigue. In terms of quality of life, over 90.0% of patients thought that ITP had a negative impact on their working life/studies, daily tasks, energy, capacity to exercise, and sexual life. With regard to emotion, 60.8% (174/286) patients thought that ITP had a greater impact on overall emotion, concerns about the fluctuation in platelet level (74.8%, 214/286) , disease itself (71.7%, 205/286) and disease progression (68.9%, 197/286) were the common issues, which were similar to the physicians' evaluations. Both physicians and patients agreed that reducing spontaneous bleeding, maintaining a healthy blood count and improving quality of life were the top three important treatment goals. Physicians considered reducing bleeding risk as the most important factor for decision making. Physicians believed that patients receiving glucocorticoid (54.9%, 56/102) were most likely to succeed in achieving sustained response while patients had the best response to thrombopoietin receptor agonist (TPO-RA) treatment, with about 83.9% (240/286) being satisfied with the overall effectiveness of TPO-RA. Conclusions: Physicians in the I-WISh Chinese subgroup had low awareness on patients' fatigue and anxiety. The quality of life and emotion of patients were significantly negatively affected by ITP. There are differences in the selection of treatments between physicians and patients, suggesting that physicians should raise concerns about the quality of life of ITP patients and make individualized treatment options through physician-patient shared decisions. 目的: 探讨原发免疫性血小板减少症(ITP)对患者生活质量和情绪健康的影响及医患双方对治疗方法的认知。 方法: 该项研究为I-WISh国际调研的中国亚组分析,共102名医生和286例ITP患者参与调研,调研结果采用描述性分析。 结果: 疲劳和对血小板计数不稳定的焦虑是ITP患者在治疗后的主要症状,而医生对患者疲劳、焦虑症状的报告不充足。超过90.0%的患者认为ITP对他们的工作或学习、日常事务、体能、运动能力和性生活产生了负面影响。60.8%(174/286)的患者认为ITP对情绪影响较大,其中对血小板计数波动(74.8%,214/286)、疾病本身(71.7%,205/286)及病情恶化(68.9%,197/268)的担忧占主要方面,医生也给出了类似的评价。医患双方均认为减少自发出血、维持安全稳定的血小板水平和改善生活质量是ITP最重要的三个治疗目标,其中降低出血风险是影响医生治疗决策的首要因素。此外,医生认为糖皮质激素(54.9%,56/102)最有可能使患者达到持续有效的治疗目标,而患者对血小板生成素受体激动剂(TPO-RA)的反馈最好,且83.9%(240/286)的患者对TPO-RA的疗效表示满意。 结论: ITP对患者生活质量和情绪存在巨大影响,但中国医生对ITP患者疲劳和焦虑症状认识不足。在ITP诊治过程中医患应加强沟通,共同决策,以制定合适的个体化治疗方案。.
引用
- Wang RT, Liu XG, Hou Y, et al. [A physician-patient survey for primary immune thrombocytopenia: Chinese subgroup analysis of I-WISh International Survey]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34218578. doi:10.3760/cma.j.issn.0253-2727.2021.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。